Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer
Complete the form below to unlock access to ALL audio articles.
Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells.
The programmed death 1 (PD-1) pathway dampens immune responses to tumor cells, and several clinical trials have shown favorable outcomes by targeting PD-1 or its ligand PD-1L.
In JCI Insight, David Hafler and colleagues at Yale University and Massachusetts Institute of Technology examined PD-1-expressing regulatory T cells in glioblastoma multiforme, an extremely aggressive form of brain cancer.
Regulatory T cells normally constrain immune responses and keep other types of T cells from mounting hyper-aggressive responses.
Although anti-PD1 therapy is generally thought to promote conventional T cell activity, the Hafler team now reports that PD-1 expression on regulatory T cells from the tumors of glioblastoma multiforme patients correlates with regulatory T cell dysfunction.
They also found that glioblastoma multiforme patients treated with a PD-1 blocking antibody had a higher proportion of dysfunctional regulatory T cells.
These observations suggest the possibility that PD-1 targeting therapies could work, in part, by driving further regulatory T cell dysfunction.
Future studies will be needed to more fully understand the contribution of this pathway to anti-tumor effects.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Lowther DE et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight, Published April 21 2016. doi: 10.1172/jci.insight.85935